AbbVie Boosts Shire Bid as It Pursues Tax Inversion Deal


WATCH: More market update videos on TheStreet TV | More videos from Brittany Umar

NEW YORK (TheStreet) -- Drugmaker AbbVie is raising its takeover offer for Irish pharmaceutical company Shire for a fourth time to $51.6 billion, an 11% increase from its prior bid, as it seeks a tax inversion deal.

VIDEO TRANSCRIPT:

Drugmaker AbbVie (ABBV) is raising its takeover offer for Irish pharmaceutical company Shire (SHPG) for a fourth time as it attempts to secure a tax inversion deal.

Under the new offer, AbbVie raised its cash-and-stock bid by 11% to more than $51 billion.  Shire already rejected AbbVie's previous bid of $46 billion, saying it significantly undervalued the company.

As part of the deal, AbbVie would acquire Shire and move the combined company's tax home to the U.K., which has a main corporate tax rate of 21%, below the U.S. federal corporate tax rate of 35%. AbbVie has said it would see its overall tax rate cut to 13% by 2016 as a result of the acquisition and inversion.

Shire did not immediately reject the offer, saying its board would meet to consider the proposal. Under British law, AbbVie has until July 18 to make a formal offer to acquire Shire or step away from a deal for up to six months.

In New York, I'm Brittany Umar for TheStreet.

-- Written by Brittany Umar in New York.

More from Opinion

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider